Table 2.

Structure of known inhibitors of Bcl-2, Bcl-xL and Mcl-1.

Agent	Target proteins	Pre-clinical and clinical trials‡§
	Bcl-2, Bcl-xL, Bcl-w and Mcl-1	Sponsor: National Cancer Institute (USA) Condition: brain and CNS tumors (Phase I) Sponsor: Ascenta Therapeutics Condition: prostate and small-cell lung, Phase I/II; non-small cell lung, lymphoma (Phase II) Sponsor: Mayo Clinic Condition: lung (Phase II)
	Bcl-2 and Bcl-xL	Sponsor: University of Arizona¶ (USA) Condition: prostate, Phase I; leukemia (Phase II) Sponsor: MD Anderson Cancer Center‡ (USA) Condition: breast (Phase I)
	Bcl-2 and Bcl-xL
	Bcl-xL	Sponsor: Harvard University (USA) Preclinical
	Bcl-xL	Sponsor: Harvard University (USA) Preclinical
	Bcl-2, Bcl-xL, Bcl-w and Mcl-1	Sponsor: Gemin X and Cephalon Condition: lung, leukemia, lymphoma, unspecified solid tumors (Phase I/II); mylelofibrosis (Phase II); hematological malignancies (Phase I)
Agent	Target proteins	Sponsor
	Bcl-2
		Sponsor: Ricerca Biosciences Preclinical
	Bcl-2
	Bcl-2, Bcl-xL	Sponsor: Novartis Pharmaceuticals Condition: multiple myeloma (Phase III) Sponsor: medac GmbH Condition: leukemia (Phase I/II) Sponsor: Centre Francois Baclesse Condition: ovarian (Phase II)
	Bcl-xL	Sponsor: Harvard University Preclinical

^‡The condition gives a general description of the cancers or cancer-related diseases involved in the study and is not an exhaustive list.

^§The phase of the trial is listed in parenthesis following the related condition.

^¶In collaboration with the US National Cancer Institute.